FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285514> ?p ?o ?g. }

• W4379285514 endingPage "1081" @default.
• W4379285514 startingPage "1081" @default.
• W4379285514 abstract "1081 Background: CDK4/6i plus ET is standard of care first-line (1L) therapy for hormone receptor positive (HR+), HER2- aBC. While molecular analyses from trials and pts have identified several mechanisms of resistance to CDK4/6i plus ET, currently, no biomarkers (outside of hormone status) are used for therapy selection. We utilized RW data to assess impact of putative baseline CDK4/6i+ET resistance alts (CDK4/6i+ET-R) on clinical outcomes among pts with aBC treated with CDK4/6i. Methods: Pts with aBC were identified via the Guardant INFORM database; those with a ctDNA test within 90 days prior to CDK4/6i start were included in this analysis. Based on previous studies, oncogenic or likely oncogenic alterations (as characterized by OncoKB) in the following genes were considered CDK4/6i+ET-R alts: RB1, PTEN, AKT1, CCNE1, ERBB2, FGFR1, FGFR2, and KRAS. Pts with >1 CDK4/6i+ET-R alt were compared to pts without any CDK4/6i-R alts. Kaplan-Meier plots, log-rank tests (LR) and multivariate Cox proportional hazards models (HR) adjusted (adj) for age, sex, year of ctDNA test and line of therapy were used to assess differences in time to next treatment (TTNT) and overall survival (OS). Results: 1075 pts with aBC treated with CDK4/6i (27% receiving 1L treatment) met inclusion criteria, 293 of whom (27%) had >1 alt in a CDK4/6i+ET-R gene. Pts with CDK4/6+ETi-R alts had significantly shorter TTNT (8.7 mos vs 14.2 mos, LR p=0.001; adj HR 1.36, 95%CI 1.11-1.66, adj p=0.003) and OS (28.3 mos vs 60.9 mos, LR p=<0.0001; adj HR 2.19, 95%CI 1.69-2.82, adj p=<0.0001) compared to those without. This divergence was more pronounced for patients receiving 1L CDK4/6i (TTNT: 10.7 mos vs 24.6 mos, LR p=0.006, adj HR 1.84, 95%CI 1.18-2.87, adj p=0.007; OS: 23.8 mos vs 67.3 mos, LR p<0.0001, adj HR 3.27, 95%CI 1.89-5.62, adj p<0.0001). Individual gene contributions towards less favorable TTNT are shown. Conclusions: We demonstrate via RW data that patients with >1 pre-treatment ctDNA alt in a curated list of CDK4/6i+ET-R genes have significantly worse outcomes on CDK4/6i plus ET treatment, a difference more pronounced among patients receiving 1L therapy. This data is among the first successful efforts to validate a clinically useful multi-gene clinical biomarker that has the potential to predict CDK4/6i plus ET resistance. Further exploration of this signature’s prognostic and predictive utility for CDK4/6i plus ET use is ongoing to better refine personalized treatment selection in HR+/HER2- aBC. [Table: see text]" @default.
• W4379285514 created "2023-06-05" @default.
• W4379285514 creator A5025351031 @default.
• W4379285514 creator A5026753967 @default.
• W4379285514 creator A5029733167 @default.
• W4379285514 creator A5032548225 @default.
• W4379285514 creator A5034972183 @default.
• W4379285514 creator A5046585715 @default.
• W4379285514 creator A5074681480 @default.
• W4379285514 date "2023-06-01" @default.
• W4379285514 modified "2023-10-18" @default.
• W4379285514 title "Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment." @default.
• W4379285514 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.1081" @default.
• W4379285514 hasPublicationYear "2023" @default.
• W4379285514 type Work @default.
• W4379285514 citedByCount "0" @default.
• W4379285514 crossrefType "journal-article" @default.
• W4379285514 hasAuthorship W4379285514A5025351031 @default.
• W4379285514 hasAuthorship W4379285514A5026753967 @default.
• W4379285514 hasAuthorship W4379285514A5029733167 @default.
• W4379285514 hasAuthorship W4379285514A5032548225 @default.
• W4379285514 hasAuthorship W4379285514A5034972183 @default.
• W4379285514 hasAuthorship W4379285514A5046585715 @default.
• W4379285514 hasAuthorship W4379285514A5074681480 @default.
• W4379285514 hasConcept C121608353 @default.
• W4379285514 hasConcept C126322002 @default.
• W4379285514 hasConcept C143998085 @default.
• W4379285514 hasConcept C2775930923 @default.
• W4379285514 hasConcept C2777609662 @default.
• W4379285514 hasConcept C2779744173 @default.
• W4379285514 hasConcept C2781187634 @default.
• W4379285514 hasConcept C502942594 @default.
• W4379285514 hasConcept C526805850 @default.
• W4379285514 hasConcept C530470458 @default.
• W4379285514 hasConcept C54355233 @default.
• W4379285514 hasConcept C62478195 @default.
• W4379285514 hasConcept C71924100 @default.
• W4379285514 hasConcept C86554907 @default.
• W4379285514 hasConcept C86803240 @default.
• W4379285514 hasConceptScore W4379285514C121608353 @default.
• W4379285514 hasConceptScore W4379285514C126322002 @default.
• W4379285514 hasConceptScore W4379285514C143998085 @default.
• W4379285514 hasConceptScore W4379285514C2775930923 @default.
• W4379285514 hasConceptScore W4379285514C2777609662 @default.
• W4379285514 hasConceptScore W4379285514C2779744173 @default.
• W4379285514 hasConceptScore W4379285514C2781187634 @default.
• W4379285514 hasConceptScore W4379285514C502942594 @default.
• W4379285514 hasConceptScore W4379285514C526805850 @default.
• W4379285514 hasConceptScore W4379285514C530470458 @default.
• W4379285514 hasConceptScore W4379285514C54355233 @default.
• W4379285514 hasConceptScore W4379285514C62478195 @default.
• W4379285514 hasConceptScore W4379285514C71924100 @default.
• W4379285514 hasConceptScore W4379285514C86554907 @default.
• W4379285514 hasConceptScore W4379285514C86803240 @default.
• W4379285514 hasIssue "16_suppl" @default.
• W4379285514 hasLocation W43792855141 @default.
• W4379285514 hasOpenAccess W4379285514 @default.
• W4379285514 hasPrimaryLocation W43792855141 @default.
• W4379285514 hasRelatedWork W1600219967 @default.
• W4379285514 hasRelatedWork W1921815462 @default.
• W4379285514 hasRelatedWork W1999213748 @default.
• W4379285514 hasRelatedWork W2051349689 @default.
• W4379285514 hasRelatedWork W2095630332 @default.
• W4379285514 hasRelatedWork W2257154986 @default.
• W4379285514 hasRelatedWork W2566402427 @default.
• W4379285514 hasRelatedWork W2600199136 @default.
• W4379285514 hasRelatedWork W2802690479 @default.
• W4379285514 hasRelatedWork W2887966505 @default.
• W4379285514 hasVolume "41" @default.
• W4379285514 isParatext "false" @default.
• W4379285514 isRetracted "false" @default.
• W4379285514 workType "article" @default.